Paul Josephs - 20 May 2024 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Role: Chief Executive Officer, Director
Signature: /s/ Rebecca J Hilt Attorney-In-Fact for Paul Josephs
Issuer symbol: LFCR
Transactions as of: 20 May 2024
Transactions value $: $0
Form type: 4
Filing time: 22 May 2024, 17:48:54 UTC
Next filing: 10 Dec 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LFCR	Common Stock	Award		+525K			525K	20 May 2024	Direct	F1
transaction	LFCR	Common Stock	Tax liability		-8.98K	-1.71%		516K	20 May 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LFCR	Performance-Based Restricted Stock Units	Award	$0	+1.5M		$0.00^*	0	20 May 2024	Common Stock	1.5M		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2	Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3	Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones.
F4	The performance-based restricted stock units vest, if it all, based on the Issuer's achievement of certain stock prices.